Blood-based biomarkers in Alzheimer's disease: Future directions for implementation
Document Type
Article
Abstract
INTRODUCTION: Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non-invasive blood-based biomarker (BBBM) test for detection of amyloid-β pathology may reduce diagnostic barriers and facilitate DMT initiation. OBJECTIVE: To explore heterogeneity in AD care pathways and potential role of BBBM tests. METHODS: Survey of 213 healthcare professionals/payers in US/China/UK/Germany/Spain/France and two advisory boards (US/Europe). RESULTS: Current diagnostic pathways are heterogeneous, meaning many AD patients are missed while low-risk patients undergo unnecessary procedures. Confirmatory amyloid testing (cerebrospinal fluid biomarkers/positron emission tomography) is utilized in few patients, resulting in diagnostic/treatment delays. A high negative-predictive-value test could streamline the diagnostic pathway by reducing unnecessary procedures in low-risk patients; supporting confirmatory testing where needed. Imminent approval of DMTs will increase need for fast and reliable AD diagnostic tests. DISCUSSION: An easy-to-use, accurate, non-invasive BBBM test for amyloid pathology could guide diagnostic procedures or referral, streamlining early diagnosis and DMT initiation. HIGHLIGHTS: This study explored AD care pathways and how BBBM may meet diagnostic demandsCurrent diagnostic pathways are heterogeneous, with country and setting variationsMany AD patients are missed, while low-risk patients undergo unnecessary proceduresAn easy-to-use, accurate, non-invasive BBBM test for amyloid pathology is neededThis test could streamline early diagnosis of amyloid pathology and DMT initiation.
Publication Date
1-1-2023
Publication Title
Alzheimer's & dementia (Amsterdam, Netherlands)
ISSN
2352-8729
Volume
15
Issue
4
First Page
e12508
PubMed ID
38058357
Digital Object Identifier (DOI)
10.1002/dad2.12508
Recommended Citation
Suridjan, Ivonne; van der Flier, Wiesje M.; Monsch, Andreas U.; Burnie, Nerida; Baldor, Robert; Sabbagh, Marwan; Vilaseca, Josep; Cai, Dongming; Carboni, Margherita; and Lah, James J., "Blood-based biomarkers in Alzheimer's disease: Future directions for implementation" (2023). Neurology. 1706.
https://scholar.barrowneuro.org/neurology/1706